By ThinkSabio #ThinkSabio Latest News
First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema.
Intellia expects to complete enrollment in 2H'25 and submit a BLA in 2026
Subscribe
for ThinkSabio Updates !
We'll keep you up to date about our Stocks, Sec Alerts , Trendings Stocks etc..